Rentschler Biopharma Invests Heavily in German Headquarters

  • Construction of a new buffer media facility in Laupheim
  • Largest investment in the German site; project duration of approx. three years
  • Continuous modernization, automation, and digitalization of the site

LAUPHEIM, Germany, Oct. 24, 2024 — Rentschler Biopharma SE, a global leader in contract development and manufacturing (CDMO) for biopharmaceuticals, including advanced therapy medicinal products (ATMPs), is building a cutting-edge buffer media station at its headquarters in Laupheim. This new facility aims to boost production efficiency and modernize the site to meet the evolving needs of clients and patients.

“This investment underscores our commitment to the long-term growth of our Laupheim site, which plays a key role in Germany’s biotechnology landscape. This expansion will strengthen our competitive position in one of the fastest-growing industries globally. As a company with 150 years of tradition, Rentschler Biopharma has always prioritized forward-looking, strategic planning, which has enabled us to achieve sustainable growth as an independent family-owned company. I would like to express my gratitude to all colleagues involved in the planning and execution of this significant project,” said Benedikt von Braunmühl, Chief Executive Officer of Rentschler Biopharma. “Government support for a German national pharmaceutical strategy is an important signal for the industry as a whole. While our focus remains on strengthening global partnerships, this investment in our German site plays a crucial role in ensuring supply chain reliability and advancing our long-term growth strategy.”

The new four-story buffer media station, covering 34,000 square meters, is scheduled to be operational by 2028. This state-of-the-art facility will integrate seamlessly with the existing infrastructure, offering faster and more efficient processes, as well as ergonomically designed workstations for optimal employee experience. The new building, along with all technical systems, will meet the highest quality and automation standards, and, through its state-of-the-art equipment, support Rentschler Biopharma’s environmental and sustainability goals.

“As a CDMO, we are committed to supporting our clients in transforming innovative ideas into life-saving biopharmaceuticals. Patients with rare and severe diseases rely on the therapies we develop and manufacture in partnership with our clients. This project is therefore not just an investment in our infrastructure, it is a fundamental part of our work, creating sustainable value for the benefit of our clients and for patients and ensuring the availability of therapeutics in Germany and globally. With the new buffer media station, we are making a significant contribution to operational excellence, enabling us to respond rapidly to growing client demands. We are also creating a more ergonomic work environment for our employees and positioning our site for future success,” added Christiane Bardroff, Chief Operating Officer of Rentschler Biopharma.

The new facility will feature three media tanks and six buffer tanks, providing ample space and capacity for the production of buffer solutions and media. Buffer and media preparation will be conducted in separate areas to ensure the highest standards of hygiene and safety. Additionally, the facility will be connected to the in-house logistics system and the piping system for upstream and downstream processes.

Detailed planning for the new building is underway, and construction is scheduled to begin in spring 2025. Completion and operational launch are planned by the end of 2027, allowing the full potential of the new buffer media station to be realized by 2028.

About Rentschler Biopharma SE

Rentschler Biopharma is a leading contract development and manufacturing organization (CDMO) solely focused on client projects. The company offers process development and manufacturing of biopharmaceuticals, including advanced therapies, as well as related consulting activities, project management and regulatory support. Rentschler Biopharma’s high quality is evidenced by its extensive experience and excellence as a solution partner for its clients. A robust quality management system, a well-established operational excellence philosophy and advanced technologies ensure product quality and productivity at each development and manufacturing step. Rentschler Biopharma is a family-owned company with about 1,400 employees, headquartered in Laupheim, Germany, with operations in Milford, MA, USA and Stevenage, UK. In 2024, the company joined the United Nations Global Compact, highlighting Rentschler Biopharma’s commitment to sustainability. For further information about the company, please visit . Follow Rentschler Biopharma on .

Contact:
Rentschler Biopharma SE
Dr. Latika Bhonsle-Deeng
Global Head of Communications
Phone: +49-7392-701-874
   
Media inquiries:  
MC Services AG
Eva Bauer
Phone: +49-89-210228-0
U.S.
Laurie Doyle
Phone: +1-339-832-0752
   

For high-resolution images, please contact .